{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:18Z","timestamp":1791478218108,"version":"4.3.4"},"reference-count":43,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth &amp; Development Office","doi-asserted-by":"publisher","award":["PATH  MVPP 300341-108"],"award-info":[{"award-number":["PATH  MVPP 300341-108"]}],"id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Towards achieving the goal of eliminating epidemic outbreaks of meningococcal disease in the African meningitis belt, a pentavalent glycoconjugate vaccine (NmCV-5) has been developed to protect against Neisseria meningitidis serogroups A, C, Y, W and X. MenA and X polysaccharides are conjugated to tetanus toxoid (TT) while MenC, Y and W polysaccharides are conjugated to recombinant cross reactive material 197 (rCRM197), a non-toxic genetic variant of diphtheria toxin. This study describes quality control testing performed by the manufacturer, Serum Institute of India Private Limited (SIIPL), and the independent control laboratory of the U.K. (NIBSC) on seven clinical lots of the vaccine to ensure its potency, purity, safety and consistency of its manufacturing. In addition to monitoring upstream-manufactured components, samples of drug substance, final drug product and stability samples were evaluated. This paper focuses on the comparison of the vaccine\u2019s critical quality attributes and reviews key indicators of its stability and immunogenicity. Comparable results were obtained by the two laboratories demonstrating sufficient levels of polysaccharide O-acetylation, consistency in size of the bulk conjugate molecules, integrity of the conjugated saccharides in the drug substance and drug product, and acceptable endotoxin content in the final drug product. The freeze-dried vaccine in 5-dose vials was stable based on molecular sizing and free saccharide assays. Lot-to-lot manufacturing consistency was also demonstrated in preclinical studies for polysaccharide-specific IgG and complement-dependent serum bactericidal activity for each serogroup. This study demonstrates the high quality and stability of NmCV-5, which is now undergoing Phase 3 clinical trials in Africa and India.<\/jats:p>","DOI":"10.3390\/pathogens10080928","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T04:29:14Z","timestamp":1627014554000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-3536","authenticated-orcid":false,"given":"Barbara","family":"Bolgiano","sequence":"first","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eil\u00eds","family":"Moran","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Beresford","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Gao","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Care","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trusha","family":"Desai","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Karin","family":"Nordgren","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-0333","authenticated-orcid":false,"given":"Timothy R.","family":"Rudd","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Feavers","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Bore","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Patni","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Gavade","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Mallya","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kale","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Sharma","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Goel","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gairola","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas","family":"Hattarki","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Avalaskar","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamraju D.","family":"Sarma","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"LaForce","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ravenscroft","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Khandke","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-6149","authenticated-orcid":false,"given":"Mark R.","family":"Alderson","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev M.","family":"Dhere","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambhaji S.","family":"Pisal","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"ref_1","unstructured":"(2019). International Coordination Group on Vaccine Provision for Epidemic Meningitis: Report of the Annual Meeting: Geneva, 18 September 2018, World Health Organization. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/279828\/WHO-WHE-IHM-2019.1-eng.pdf."},{"key":"ref_2","unstructured":"(2019). Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 18, 459\u2013480."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"010411","DOI":"10.7189\/jogh.09.010411","article-title":"Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: A systematic review","volume":"9","author":"Kyaw","year":"2019","journal-title":"J. Glob. Health"},{"key":"ref_4","unstructured":"(2018). Meningococcal Meningitis, World Health Organization. Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/meningococcal-meningitis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alderson, M.R., Welsch, J.A., Regan, K., Newhouse, L., Bhat, N., and Marfin, A.A. (2021). Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040771"},{"key":"ref_6","unstructured":"(2010). Immunological Basis for Immunization Series: Module 15: Meningococcal Disease, World Health Organization. Available online: https:\/\/www.who.int\/immunization\/research\/development\/Meningococcal_disease_module15.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/21645515.2017.1391434","article-title":"Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVac(R))","volume":"14","author":"Kulkarni","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1093\/infdis\/jiz358","article-title":"Bacterial Meningitis Epidemiology in Five Countries in the Meningitis Belt of Sub-Saharan Africa, 2015\u20132017","volume":"220","author":"Soeters","year":"2019","journal-title":"J. Infect Dis."},{"key":"ref_9","unstructured":"(2019). Epidemic meningitis control in countries in the African meningitis belt, 2018. Wkly Epidemiol Rec., 94, 179\u2013188. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311704\/WER9414_15.pdf?ua=1."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1093\/infdis\/jiz355","article-title":"Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011\u20132017","volume":"220","author":"Fernandez","year":"2019","journal-title":"J. Infect Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1473-3099(16)30253-5","article-title":"MenAfriNet consortium. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: An analysis of national surveillance data","volume":"16","author":"Sidikou","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"ref_13","unstructured":"(2020). No authors listed. Control of epidemic meningitis in countries in the African meningitis belt, 2019. Wkly Epidemiol Rec., 95, 133\u2013144."},{"key":"ref_14","unstructured":"(2011). WHO\u2013Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec., 47, 521\u2013540. Available online: https:\/\/www.who.int\/wer\/2011\/wer8647.pdf?ua=1."},{"key":"ref_15","unstructured":"(2021). WHO-Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)-List of Prequalified Vaccines-Menactra, World Health Organization. Available online: https:\/\/extranet.who.int\/pqweb\/content\/menactra."},{"key":"ref_16","unstructured":"(2021). WHO-Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)-List of Prequalified Vaccines-Menveo, World Health Organization. Available online: https:\/\/extranet.who.int\/pqweb\/content\/menveo."},{"key":"ref_17","unstructured":"(2021). WHO-Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)-List of Prequalified Vaccines-Nimenrix, World Health Organization. Available online: https:\/\/extranet.who.int\/pqweb\/content\/nimenrix."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/infdis\/jiz297","article-title":"Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines","volume":"220","author":"Alderson","year":"2019","journal-title":"J. Infect Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.xphs.2018.03.002","article-title":"Analytical Comparability Assessments of 5 Recombinant CRM(197) Proteins From Different Manufacturers and Expression Systems","volume":"107","author":"Hickey","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: A phase 1, single-centre, double-blind, randomised, controlled study","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biologicals.2013.12.001","article-title":"Process development and immunogenicity studies on a serogroup \u2018X\u2019 Meningococcal polysaccharide conjugate vaccine","volume":"42","author":"Chilukuri","year":"2014","journal-title":"Biologicals"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMoa2013615","article-title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Malian Toddlers","volume":"384","author":"Tapia","year":"2021","journal-title":"NEJM"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Davies, J.G., Gao, D., Kim, Y.J., Harris, R., Cash, P.W., Schofield, T.L., Zhang, R., and Qin, Q. ICH Q5C Stability Testing of Biotechnological\/Biological Products. ICH Qual. Guidel., 2017.","DOI":"10.1002\/9781118971147.ch12"},{"key":"ref_24","unstructured":"(1980). Requirements for Meningococcal Polysaccharide Vaccine. Annex 2. WHO Technical Report Series-Number 658, World Health Organization. Available online: https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/meningococcal\/WHO_TRS_658_(part2)_MeningA6.pdf."},{"key":"ref_25","unstructured":"(2011). Recommendations to Assure the Quality, Safety and Efficacy of Group A Meningococcal Conjugate Vaccines. Annex 2. WHO Technical Report Series-Number 962, World Health Organization. Available online: https:\/\/www.who.int\/biologicals\/vaccines\/Annex_2_WHO_TRS_962.pdf."},{"key":"ref_26","unstructured":"(2004). Recommendations for the Production and Control of Meningococcal Group C Conjugate Vaccines. Annex 2. WHO Technical Report Series-Number 924, World Health Organization. Available online: https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/meningococcal\/WHO_TRS_924_MeningA2_102-128.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.vaccine.2019.05.050","article-title":"O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes","volume":"37","author":"Hitri","year":"2019","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.vaccine.2015.01.046","article-title":"Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines","volume":"33","author":"Lockyer","year":"2015","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Berti, F. (2018). Multivalent meningococcal conjugate vaccines: Chemical conjugation strategies used for the preparation of vaccines licensed or in clinical trials. Carbohydrate-Based Vaccines: From Concept to Clinic, ACS Publications.","DOI":"10.1021\/bk-2018-1290.ch006"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1016\/j.vaccine.2014.09.063","article-title":"Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt","volume":"32","author":"Tunheim","year":"2014","journal-title":"Vaccine"},{"key":"ref_32","unstructured":"Ravenscroft, N., Omar, A., Haralson, S., Alderson, M.R., LaForce, F.M., Gao, F., Beresford, N., Moran, E., Care, R., and Swann, C. (2015, January 4\u20135). Analytical Methods and Evaluation of a Pentavalent Meningococcal Conjugate Vaccine Candidate [Poster]. Proceedings of the Meningitis and Septicaemia in Children and Adults, Meningitis Research Foundation, London, UK."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nunnally, B.K., Turula, V.E., and Sitrin, R.D. (2015). Glycoconjugate Vaccines. Vaccine Analysis: Strategies, Principles, and Control, Springer.","DOI":"10.1007\/978-3-662-45024-6"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.vaccine.2014.01.038","article-title":"Benefits of using vaccines out of the cold chain: Delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin","volume":"32","author":"Zipursky","year":"2014","journal-title":"Vaccine"},{"key":"ref_35","unstructured":"(2013). Use of MenAfriVac\u2122 (Meningitis A Vaccine) in a Controlled Temperature Chain (CTC) During Campaigns, World Health Organization. Available online: https:\/\/www.who.int\/immunization\/documents\/WHO_IVB_13.04_5_6\/en\/."},{"key":"ref_36","unstructured":"(2016). Guidelines on the Stability Evaluation of Vaccines for Use Under Extended Controlled Temperature Conditions. Annex 5. WHO Technical Report Series-Number 999, World Health Organization. Available online: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/Annex_5_Guidelines_on_Stability_evaluation_vaccines_ECTC.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/21645515.2019.1606972","article-title":"Classical and novel strategies to develop a Shigella glycoconjugate vaccine: From concept to efficacy in human","volume":"15","author":"Barel","year":"2019","journal-title":"Hum. Vaccin Immunother"},{"key":"ref_38","unstructured":"(2020). Defeating Meningitis by 2030 Global Road Map (Version 26 October 2020), World Health Organization. Available online: https:\/\/www.who.int\/publications\/m\/item\/defeating-meningtis-by-2030-global-road-map-(version-20-october-2020)."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","article-title":"Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture","volume":"30","author":"Jones","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biologicals.2021.01.001","article-title":"Saccharide dosage content of meningococcal polysaccharide conjugate vaccines determined using WHO International Standards for serogroup A, C, W, Y and X polysaccharides","volume":"70","author":"Gao","year":"2021","journal-title":"Biologicals"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.vaccine.2013.05.098","article-title":"Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: Optimisation of hydrolysis conditions and chromatographic methods","volume":"31","author":"Cook","year":"2013","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2017.03.066","article-title":"Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM(197), DT and TT glycoconjugate vaccines","volume":"35","author":"Beresford","year":"2017","journal-title":"Vaccine"},{"key":"ref_43","unstructured":"(2013). CombiStats v5, EDQM Council of Europe. Available online: https:\/\/www.edqm.eu\/combistats\/."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/8\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:33:46Z","timestamp":1760164426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/8\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["pathogens10080928"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10080928","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]}}}